Please wait while we open this resource.
K
Clinical reviews
THE FENOFIBRATE ERA
null
PDF202512 pages1.1 MB
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality, despite advancements in lipid-lowering therapies. Fibrates have historically been used to manage dyslipidaemia, but their use has declined due to neutral outcomes in large trials. This document explores the potential continued relevance of fibrates, especially for specific patient subgroups facing therapeutic challenges, such as those with insulin resistance or severe hypertriglyceridaemia. The review also considers the expanding potential of fibrates in managing metabolic dysfunction-associated conditions.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
SURVIVAL AFTER INITIAL STRESS TESTING VS ANATOMIC TESTING IN SUSPECTED CORONARY ARTERY DISEASE
Same clinical topic · Cardiology
PRACTICAL CARDIO-ONCOLOGY
Same clinical topic · Cardiology
OXFORD CARDIOLOGY LIBRARY: Hypertension
Same clinical topic · Cardiology
CARDIAC INVOLVEMENT IN PARASITIC INFECTIONS
Same clinical topic · Cardiology
The Athlete’s ECG
Same clinical topic · Cardiology
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review
Same clinical topic · Cardiology
Current ECG Aspects of Interatrial Block
Same clinical topic · Cardiology
Arrhythmic mitral valve prolapse in 2023: Evidence-based update
Same clinical topic · Cardiology
INTERPRETING THE NORMAL PACEMAKER
Same clinical topic · Cardiology